We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Fecal Immunochemical Test Screens for Colon Cancer

By LabMedica International staff writers
Posted on 14 Dec 2010
A test that detects blood in the stool is the most cost effective method for screening for colon cancer. More...
An economic evaluation of screening methods for colorectal cancer found that annual testing by the fecal immunochemical methods was more effective than other methods.

The fecal immunochemical test has high sensitivity and specificity, and might improve participation rates through increased patient acceptability. This would reduce the risk of colorectal cancer and colorectal cancer related deaths, and reduce healthcare costs in comparison to all other screening strategies and to no screening. In a model devised by scientists at University of Calgary, (Alberta, Canada), the authors used an incremental cost utility analysis, a sophisticated modeling technique, and two hypothetical patient cohorts (individuals with an "average risk,” i.e., no family history of colorectal cancer, aged 50-64 and 65-75) to compare different colorectal cancer screening methods.

The authors found that annual fecal immunochemical testing was more effective and less costly compared to all strategies (including no screening). Using this screening modality, among the lifetimes of 100,000 average-risk patients, the number of deaths from colorectal cancer was reduced from 1,393 to 457. Even after the authors accounted for many different scenarios, screening for colorectal cancer with fecal immunochemical testing remained the most cost effective screening option.

Clinical guidelines recommends screening for colorectal cancer in average risk individuals from 50 years old, yet some countries, such as the UK, do not currently have population-based colorectal cancer screening. In addition, many countries with colorectal cancer screening programs do not offer a choice of screening method. The authors concluded: "Health policy decision makers should consider prioritizing funding for colorectal cancer screening using fecal immunochemical testing." The study was published online on November 23, 2010, in the open access journal Public Library of Science (PLoS) Medicine.

Related Links:
University of Calgary




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.